Related Experiment Video
Updated: Jul 9, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An
Journal of Drugs in Dermatology : JDD
|December 5, 2023
Summary
The 40-gene expression profile (40-GEP) test offers crucial prognostic insights for cutaneous squamous cell carcinoma (cSCC) beyond traditional staging. This consensus guidance aims to integrate 40-GEP testing into clinical practice for better metastasis risk assessment.
Area of Science:
- Dermatology
- Oncology
- Genomics
Background:
- Cutaneous squamous cell carcinoma (cSCC) incidence is rising, with metastasis being a key driver of mortality.
- Current staging systems for cSCC have limitations in predicting metastatic events.
- The 40-gene expression profile (40-GEP) test aids in stratifying cSCC patients by metastasis risk.
Purpose of the Study:
- To review literature on gene expression profile (GEP) testing for cSCC prognosis.
- To develop consensus statements guiding dermatologists on GEP test utilization.
- To enhance clinical decision-making for cSCC management.
Main Methods:
- Comprehensive literature search of PubMed, EMBASE, and Scopus.
- Expert panel review of 21 selected articles by 8 dermatologists.
- Modified Delphi process for consensus statement approval and SORT rating.
Main Results:
- 157 articles were initially identified, with 21 selected for detailed review.
- Seven consensus statements were unanimously adopted by the expert panel.
- Six statements received a Strength of Recommendation (SORT) grade of "A", one received "C".
Conclusions:
- The 40-GEP test provides prognostic information independent of standard pathological staging.
- Integrating GEP testing into guidelines can improve patient stratification for metastasis risk.
- This approach may lead to reduced morbidity and mortality in cSCC patients.
